Schwartz said, “During my time leading eganelisib’s development, I have been extremely encouraged by the data generated from MARIO-275, MARIO-3 and MARIO-1, which demonstrate notable improvements in overall survival and progression free survival in bladder cancer and initial evidence of durable clinical activity in triple negative breast cancer. I look forward to working to advance eganelisib in registration enabling studies to leverage the benefit shown for patients with urothelial cancer and triple negative breast cancer, including in patients who are PD-L1 negative for whom treatment options are limited.”ĭr. These eganelisib data underscore the importance of reprogramming macrophages in the tumor microenvironment to improve outcomes for patients with some of the greatest unmet needs in solid tumors. Ilaria said, “I’m thrilled to join Infinity at this important time in the development of eganelisib given the strength of the data generated to date across multiple indications and treatment settings which provide strong evidence that eganelisib has the potential to be a transformative therapy in immuno-oncology. “Robert’s extensive experience in drug development will be critically important as we build upon the compelling eganelisib data presented over the last year and initiate future studies to maximize eganelisib’s considerable potential.”ĭr. “Robert’s deep expertise in oncology drug development, with a focus in immuno-oncology – most recently leading the Celgene/BeiGene PD-1 inhibitor collaboration and Bristol Myers Squibb’s CTLA-4 program, will be a tremendous asset to Infinity at this exciting point in the trajectory of eganelisib’s development,” said Adelene Perkins, Chief Executive Officer and Chair, Infinity Pharmaceuticals. In addition, Brian Schwartz, M.D., will be transitioning from his role as Consulting Chief Physician to the Infinity Board of Directors. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer, today announced the appointment of Robert Ilaria, Jr., M.D. Robert Schwartz is also an active physician scientist focused on developing and building models of human liver disease in vitro. He uses stem cell biology, hepatocyte biology and incorporates engineering techniques to better understand human liver disease with the goal to improve clinical therapy.CAMBRIDGE, Mass.-( BUSINESS WIRE)- Infinity Pharmaceuticals, Inc. His interests include viral hepatitis, autoimmune causes of liver disease, Non-Alcoholic Fatty Liver Disease as well as metabolic causes of liver disease.ĭr. Schwartz’s focuses on the care of patient with liver disease. Louis and his fellowship training in Gastroenterology and Hepatology at the Brigham and Women’s Hospital. He completed his Internal Medicine residency at Barnes-Jewish Hospital at Washington University in St. in Biomedical Engineering from the University of Minnesota. in Chemical Engineering from the Cooper Union and his M.D. Weill Medical College of Cornell University and an Attending Physician, New York-Presbyterian Hospital Cornell campus. Robert Schwartz is an Assistant Professor of Medicine at the Sanford I.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |